News | Breast Density | January 13, 2021

DenseBreast-info Launches Updated Website

DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content

DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content

January 13, 2021 — DenseBreast-info.org (DB-I) invites health providers seeking the most up-to-date medically-sourced educational materials about the screening and risk implications of dense breast tissue and value of supplemental screening to visit the newly re-launched DB-I website at www.DenseBreast-info.org. Originally launched in 2015, the DB-I website has continued to evolve to meet the needs of providers and patients in the United States and around the world on the topic of breast density with expanded content and educational tools. In addition to featuring a new look, the DB-I website has been revamped to support a more user-friendly experience and address the increasing reach of the DB-I website, growing global interactions and to provide easier access to the substantial volume of information. New educational tools and resources include:

Patient Resource Section – features downloadable education resources in 14 languages

Expanded Spanish-Language Hub – updated screening guidance and FAQs

State Density Inform Laws – new downloads and searchable Patient Inform and Insurance legislation

DB-I published research/webinars

“As the conversation around breast density and personalized screening grows, the need for high quality medically sourced educational materials and tools has also increased. With more than 200,000 visits to the DB-I website in 2020 and nearly 300,000 projected for 2021, it is critical to continually add resources, as well as streamline the website to give providers quick and easy access to important content,” said JoAnn Pushkin, Executive Director, DenseBreast-info.

For more information: densebreast-info.org/

Related Content

Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...
Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
News | Breast Imaging | January 04, 2021
January 4, 2021 — Smart Breast Corporation (SmartBreast), a privately held company focused on...